newsfilter
← Latest News
Business Wire·

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

EKTERLY to be added to the Orphan Register and awarded 10 years of market exclusivity KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) of